The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InThe Slim family has increased its strategic stake in ProKidney Corp to 36% by holding over 73 million Class A shares, following a massive conversion to solidify voting power. In a new institutional development, Cormorant Asset Management disclosed a significant 9.71% passive stake in Bright Minds Biosciences Inc, holding 950,000 common shares through its Global Healthcare Master Fund. Parallel to this, Vanguard Group revealed new positions exceeding 5% in both Victoria's Secret & Co and Synaptics Inc, signaling robust interest in the retail and semiconductor sectors. Adding to the wave of shifts, a new filing was recorded for Arrowhead Pharmaceuticals, indicating fresh ownership movements. These activities, alongside recent positions in Veralto and Vertex Pharmaceuticals, underscore a broader trend of portfolio diversification by global asset managers. Analysts view the Slim family's consolidation and Cormorant's entry into biotech as strategic moves to secure long-term growth opportunities.